Abstract
With the focus in healthcare around improving quality while reducing costs the clinical and economic management around the use of medications in the inpatient and outpatient settings is critical. In September 2014, drug expenditures increased 12.2 % overall, 13.3 % in clinics, and 4.0 % inpatient. Projections for 2015 are expected to increase by 9 %. Therefore, a variety of drug utilization strategies should be implemented across the healthcare sector including more deployment of pharmacists into direct patient care roles, clinical decision support, and electronic order sets. Meanwhile, specialty medications, used to treat diseases, such as rheumatoid arthritis, cystic fibrosis, Crohn’s disease, and cancer, have quickly been infused into the market resulting in strong patient outcomes but high expense and fragmentation of care. Retail and mail-order pharmacy services remain unchanged but home infusion is growing due to lower associated total cost of care. Managed care and government programs continue to evolve with healthcare cost constraints utilizing formulary management, restricted networks, rebate agreements with manufacturers, and prior authorization methodologies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2015. Am J Health Syst Pharm. 2015;72:e19–38.
American Academy of Managed Care Pharmacy. AMCP guide to pharmaceutical payment methods. Executive summary. Version 3. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=16476. Accessed 21 Aug 2015.
American Society of Health-System Pharmacists. ASHP guidelines on the pharmacy and therapeutics committee and formulary system. Am J Health-Syst Pharm. 2008;43:1272–83.
Weant KA, Bowers RC, Reed J, et al. Safety and cost-effectiveness of a clinical protocol implemented to standardize the use of crotalidae polyvalent immune fab antivenom at an academic medical center. Pharmacotherapy. 2012;32:433–40.
Food and Drug Administration. Facts about generic drugs. http://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandinggenericdrugs/ucm167991.htm. Accessed 21 Aug 2015.
Food and Drug Administration. FDA approves first biosimilar product Zarxio. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm Accessed 21 Aug 2015.
Giguere A, Legare F, Grimshaw J. Printed educational materials: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2015;3. doi:10.1002/14651858.CD004398.pub3.
Delory T, De Pontfarcy A, Emirian A, et al. Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis. Eur J Clin Microbiol Infect Dis. 2013;32:1599–604.
Sonstein L, Clark C, Seidensticker S, et al. Improving adherence for management of acute exacerbation of chronic obstructive pulmonary disease. Am J Med. 2014;127:1097–104.
Flood KL, Carroll MB, Le CV, et al. Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother. 2009;7:151–8.
Selvan MS, Sittig DF, Thomas EJ, et al. Improving erythropoietin-stimulating agent administration in a multihospital system through quality improvement initiatives: a pre-post comparison study. J Patient Saf. 2011;7:127–32.
Sturm H, AustvollDahlgren A, Aaserud M, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev. 2011;10:CD006731.
O’Neal BC, Couldry RJ, Wilkinson ST, et al. Leveraging drug-utilization and external benchmarking data to drive change in prescribing behaviors. Am J Health Syst Pharm. 2012;69:1916–22.
American Pharmacists Association. Specialty pharmacy: a unique and growing industry. 2013. Retrieved from American Pharmacists Association http://www.pharmacist.com/specialty-pharmacy-unique-and-growing-industry.
U.S. Food and Drug Administration. A brief overview of risk evaluation and mitigation strategies. n.d. Retrieved from U. S. Food and Drug Administration: http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf.
Academy of Managed Care Pharmacy. Maintaining the affordability of the prescription drug benefit: how managed care organizations secure price concessions from pharmaceutical manufacturers. n.d. Retrieved from Academy of Managed Care Pharmacy: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9299.
National Home Infusion Association. Infusion FAQs. n.d. Retrieved from National Home Infusion Association. http://www.nhia.org/faqs.cfm.
Centers for Medicare and Medicaid Services. Linking quality to payment. n.d. Retrieved from Medicare.gov. https://www.medicare.gov/hospitalcompare/linking-quality-to-payment.html.
U.S. Office of Personnel Management. OPM.gov. n.d. Retrieved from Frequently Asked Questions. https://www.opm.gov/faqs/QA.aspx?fid=fd635746-de0a-4dd7-997d-b5706a0fd8d2&pid=162b86b1-5da8-45dc-ab32-3385f17e3460.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Fortier, C., Reddy, P., Thompson, N., Pulvemacher, A. (2017). Strategies for the Clinical and Financial Management of Drug Utilization. In: Lewandrowski, K., Sluss, P. (eds) Utilization Management in the Clinical Laboratory and Other Ancillary Services. Springer, Cham. https://doi.org/10.1007/978-3-319-34199-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-34199-6_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-34197-2
Online ISBN: 978-3-319-34199-6
eBook Packages: MedicineMedicine (R0)